Patient-centred approaches for the management of unpleasant symptoms in kidney disease
Tóm tắt
Từ khóa
Tài liệu tham khảo
Lockwood, M. B. et al. Physical symptom cluster subgroups in chronic kidney disease. Nurs. Res. 69, 100–108 (2020).
Weisbord, S. D. et al. Development of a symptom assessment instrument for chronic hemodialysis patients: the Dialysis Symptom Index. J. Pain. Symptom Manag. 27, 226–240 (2004).
Weisbord, S. D. et al. Prevalence, severity, and importance of physical and emotional symptoms in chronic hemodialysis patients. J. Am. Soc. Nephrol. 16, 2487–2494 (2005).
Zhang, J. C. et al. Could symptom burden predict subsequent healthcare use in patients with end stage kidney disease on hemodialysis care? A prospective, preliminary study. Ren. Fail. 42, 294–301 (2020).
Flythe, J. E. et al. Fostering innovation in symptom management among hemodialysis patients: paths forward for insomnia, muscle cramps, and fatigue. Clin. J. Am. Soc. Nephrol. 14, 150–160 (2019).
James, G. et al. Characteristics, symptom severity, and experiences of patients reporting chronic kidney disease in the PatientsLikeMe online health community: retrospective and qualitative study. J. Med. Internet Res. 22, e18548 (2020).
Kalantar-Zadeh, K., Wightman, A. & Liao, S. Ensuring choice for people with kidney failure — dialysis, supportive care, and hope. N. Engl. J. Med. 383, 99 (2020).
Cabrera, V. J., Hansson, J., Kliger, A. S. & Finkelstein, F. O. Symptom management of the patient with CKD: the role of dialysis. Clin. J. Am. Soc. Nephrol. 12, 687–693 (2017).
Cashion, A. K. & Grady, P. A. The National Institutes of Health/National Institutes of Nursing Research intramural research program and the development of the National Institutes of Health symptom science model. Nurs. Outlook 63, 484–487 (2015).
Cashion, A. K., Gill, J., Hawes, R., Henderson, W. A. & Saligan, L. National Institutes of Health symptom science model sheds light on patient symptoms. Nurs. Outlook 64, 499–506 (2016).
Dorsey, S. G. et al. Working together to advance symptom science in the precision era. Nurs. Res. 68, 86–90 (2019).
Rhee, E. P. et al. Prevalence and persistence of uremic symptoms in incident dialysis patients. Kidney360 1, 86–92 (2020).
Saligan, L. N. Collaborative framework to advance symptom science: an intramural perspective. J. Nurs. Scholarsh. 51, 17–25 (2019).
Aktas, A., Walsh, D., Hauser, K. & Rybicki, L. Should we cluster patients or symptoms? The myth of symptom clusters based on ‘depression, insomnia, pain’ and ‘depression, fatigue, pain’. BMJ Support. Palliat. Care 6, 210–218 (2016).
Laird, B. J. et al. Pain, depression, and fatigue as a symptom cluster in advanced cancer. J. Pain. Symptom Manag. 42, 1–11 (2011).
Abdel-Kader, K., Unruh, M. L. & Weisbord, S. D. Symptom burden, depression, and quality of life in chronic and end-stage kidney disease. Clin. J. Am. Soc. Nephrol. 4, 1057–1064 (2009).
Kalantar-Zadeh, K. et al. (World Kidney Day Steering Committee). Living well with kidney disease by patient and carepartner empowerment: kidney health for everyone everywhere. J. Ren. Nutr. https://doi.org/10.1053/j.jrn.2020.12.003 (2021).
Lockwood, M. B. et al. Symptom cluster science in chronic kidney disease: a literature review. West. J. Nurs. Res. 41, 1056–1091 (2019).
GBD Chronic Kidney Disease Collaboration. Global, regional, and national burden of chronic kidney disease, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 395, 709–733 (2020).
Li, P. K. et al. Kidney health for everyone everywhere-from prevention to detection and equitable access to care. depression, and fatigue as a symptom cluster in advanced cancer. Clin. Nephrol. 97, 226–232 (2020).
DeVon, H. A. et al. Systematic review of symptom clusters in cardiovascular disease. Eur. J. Cardiovasc. Nurs. 16, 6–17 (2017).
Sloan, M. et al. Medically explained symptoms: a mixed methods study of diagnostic, symptom and support experiences of patients with lupus and related systemic autoimmune diseases. Rheumatol. Adv. Pract. 4, rkaa006 (2020).
Murtagh, F. E. et al. Symptoms in advanced renal disease: a cross-sectional survey of symptom prevalence in stage 5 chronic kidney disease managed without dialysis. J. Palliat. Med. 10, 1266–1276 (2007).
Almutary, H., Bonner, A. & Douglas, C. Which patients with chronic kidney disease have the greatest symptom burden? A comparative study of advanced ckd stage and dialysis modality. J. Ren. Care 42, 73–82 (2016).
Dano, S. et al. Evaluating symptom burden in kidney transplant recipients: validation of the revised Edmonton Symptom Assessment System for kidney transplant recipients — a single-center, cross-sectional study. Transpl. Int. 33, 423–436 (2020).
Kalantar-Zadeh, K. et al. (World Kidney Day Steering Committee) Living well with kidney disease by patient and care-partner empowerment: kidney health for everyone everywhere. Kidney Int. Rep. 99, 278–284 (2021).
Lenz, E. R., Pugh, L. C., Milligan, R. A., Gift, A. & Suppe, F. The middle-range theory of unpleasant symptoms: an update. Adv. Nurs. Sci. 19, 14–27 (1997).
Lee, S. E., Vincent, C. & Finnegan, L. An analysis and evaluation of the theory of unpleasant symptoms. Adv. Nurs. Sci. 40, E16–E39 (2017).
Almutary, H., Douglas, C. & Bonner, A. Towards a symptom cluster model in chronic kidney disease: a structural equation approach. J. Adv. Nurs. 73, 2450–2461 (2017).
Linder, L. Analysis of the UCSF symptom management theory: implications for pediatric oncology nursing. J. Pediatr. Oncol. Nurs. 27, 316–324 (2010).
Cwiekala-Lewis, K., Parkyn, B. H. & Modliszewska, K. Analysis of University of California in San Francisco (UCSF) symptom management theory and theory implication for persons with neurological disorders/diseases. J. Neurolog. Neurolosurg. Nurs. 6, 55–65 (2017).
Humphreys, J. et al. Middle Range Theory For Nursing. Theory Of Symptom Management 3rd edn Vol. 7 141–164 (Springer, 2014)
Almutary, H., Douglas, C. & Bonner, A. Multidimensional symptom clusters: an exploratory factor analysis in advanced chronic kidney disease. J. Adv. Nurs. 72, 2389–2400 (2016).
Amro, A., Waldum, B., Dammen, T., Miaskowski, C. & Os, I. Symptom clusters in patients on dialysis and their association with quality-of-life outcomes. J. Ren. Care 40, 23–33 (2014).
Miaskowski, C. Future directions in symptom cluster research. Semin. Oncol. Nurs. 32, 405–415 (2016).
Kim, H. J., McGuire, D. B., Tulman, L. & Barsevick, A. M. Symptom clusters: concept analysis and clinical implications for cancer nursing. Cancer Nurs. 28, 270–282 (2005).
Yu, I. C., Huang, J. Y. & Tsai, Y. F. Symptom cluster among hemodialysis patients in Taiwan. Appl. Nurs. Res. 25, 190–196 (2012).
Ahdoot, R. S., Kalantar-Zadeh, K., Burton, J. O. & Lockwood, M. B. Novel approach to unpleasant symptom clusters surrounding pruritus in patients with chronic kidney disease and on dialysis therapy. Curr. Opin. Nephrol. Hypertens. https://doi.org/10.1097/MNH.0000000000000752 (2021).
Lee, S. J. & Jeon, J. Relationship between symptom clusters and quality of life in patients at stages 2 to 4 chronic kidney disease in Korea. Appl. Nurs. Res. 28, e13–e19 (2015).
Amro, A. et al. Symptom clusters predict mortality among dialysis patients in Norway: a prospective observational cohort study. J. Pain. Symptom Manag. 49, 27–35 (2015).
Cao, X., Tian, L. & Lin, C. Symptom clusters in patients receiving haemodialysis: a systematic review of observational studies. J. Clin. Nurs. 26, 2545–2557 (2017).
Yong, D. S. et al. Symptom burden and quality of life in end-stage renal disease: a study of 179 patients on dialysis and palliative care. Palliat. Med. 23, 111–119 (2009).
Maung, S. C., El Sara, A., Chapman, C., Cohen, D. & Cukor, D. Sleep disorders and chronic kidney disease. World J. Nephrol. 5, 224–232 (2016).
Assari, S. & Burgard, S. Black–white differences in the effect of baseline depressive symptoms on deaths due to renal diseases: 25 year follow up of a nationally representative community sample. J. Ren. Inj. Prev. 4, 127–134 (2015).
Murtagh, F. E., Sheerin, N. S., Addington-Hall, J. & Higginson, I. J. Trajectories of illness in stage 5 chronic kidney disease: a longitudinal study of patient symptoms and concerns in the last year of life. Clin. J. Am. Soc. Nephrol. 6, 1580–1590 (2011).
Song, M.-K., Paul, S., Ward, S. E., Gilet, C. A. & Hladik, G. A. One-year linear trajectories of symptoms, physical functioning, cognitive functioning, emotional well-being, and spiritual well-being among patients receiving dialysis. Am. J. Kidney Dis. 72, 198–204 (2018).
Fishbane, S. et al. A phase 3 trial of difelikefalin in hemodialysis patients with pruritus. N. Engl. J. Med. 382, 222–232 (2020).
Zhang, X., Bansal, N., Go, A. S. & Hsu, C.-Y. Gastrointestinal symptoms, inflammation and hypoalbuminemia in chronic kidney disease patients: a cross-sectional study. BMC Nephrol. 16, 211–211 (2015).
Lockwood, M. B. et al. Symptom cluster science in chronic kidney disease: a literature review. West. J. Nurs. Res. https://doi.org/10.1177/0193945918808766 (2018).
Tang, E., Bansal, A., Novak, M. & Mucsi, I. Patient-reported outcomes in patients with chronic kidney disease and kidney transplant. Part 1. Front. Med. 4, 254 (2017).
Tang, E. et al. Validation of the Patient-Reported Outcomes Measurement Information System (PROMIS)-57 and -29 item short forms among kidney transplant recipients. Qual. Life Res. 28, 815–827 (2019).
Miaskowski, C. et al. Advancing symptom science through symptom cluster research: expert panel proceedings and recommendations. JNCI https://doi.org/10.1093/jnci/djw253 (2017).
Chou, J. A. & Kalantar-Zadeh, K. Volume balance and intradialytic ultrafiltration rate in the hemodialysis patient. Curr. Heart Fail. Rep. 14, 421–427 (2017).
Kalantar-Zadeh, K. et al. Fluid retention is associated with cardiovascular mortality in patients undergoing long-term hemodialysis. Circulation 119, 671–679 (2009).
Chou, J. A. et al. Intradialytic hypotension, blood pressure changes and mortality risk in incident hemodialysis patients. Nephrol. Dial. Transpl. 33, 149–159 (2018).
Kim, H. J., Barsevick, A. M., Fang, C. Y. & Miaskowski, C. Common biological pathways underlying the psychoneurological symptom cluster in cancer patients. Cancer Nurs. 35, E1–e20 (2012).
Li, H. et al. Systematic review of the kynurenine pathway and psychoneurological symptoms among adult cancer survivors. Biol. Res. Nurs. 22, 472–484 (2020).
Song, B. C. & Bai, J. Microbiome-gut-brain axis in cancer treatment-related psychoneurological toxicities and symptoms: a systematic review. Support Care Cancer https://doi.org/10.1007/s00520-020-05739-9 (2020).
Starkweather, A. R. et al. A conceptual model of psychoneurological symptom cluster variation in women with breast cancer: bringing nursing research to personalized medicine. Curr. Pharmacogenomics Pers. Med. 11, 224–230 (2013).
Karu, N. et al. Tryptophan metabolism, its relation to inflammation and stress markers and association with psychological and cognitive functioning: Tasmanian chronic kidney disease pilot study. BMC Nephrol. 17, 171 (2016).
Mihai, S. et al. Inflammation-related mechanisms in chronic kidney disease prediction, progression, and outcome. J. Immunol. Res. 2018, 2180373 (2018).
Sato E. et al. Impact of the oral adsorbent AST-120 on organ-specific accumulation of uremic toxins: LC-MS/MS and MS imaging techniques. Toxins https://doi.org/10.3390/toxins10010019 (2017).
Brenner, B. M., Meyer, T. W. & Hostetter, T. H. Dietary protein intake and the progressive nature of kidney disease: the role of hemodynamically mediated glomerular injury in the pathogenesis of progressive glomerular sclerosis in aging, renal ablation, and intrinsic renal disease. N. Engl. J. Med. 307, 652–659 (1982).
Abe, M. & Kalantar-Zadeh, K. Haemodialysis-induced hypoglycaemia and glycaemic disarrays. Nat. Rev. Nephrol. 11, 302–313 (2015).
Besarab, A. & Coyne, D. W. Iron supplementation to treat anemia in patients with chronic kidney disease. Nat. Rev. Nephrol. 6, 699–710 (2010).
Chertow, G. M. et al. Self-reported symptoms in patients on hemodialysis with moderate to severe secondary hyperparathyroidism receiving combined therapy with cinacalcet and low-dose vitamin D sterols. Hemodial. Int. 16, 188–197 (2012).
Giannaki, C. D. et al. Non-pharmacological management of periodic limb movements during hemodialysis session in patients with uremic restless legs syndrome. ASAIO J. 56, 538–542 (2010).
Harri, J., Kasanen, A. & Pikkarainen, J. The relations between serum ultrafiltrable calcium, acidosis and tetanic symptoms in uremia. Ann. Med. Exp. Biol. Fenn. 41, 15–20 (1963).
Rhee, C. M. et al. Thyroid status, quality of life, and mental health in patients on hemodialysis. Clin. J. Am. Soc. Nephrol. 12, 1274–1283 (2017).
Kim, J. C., Kalantar-Zadeh, K. & Kopple, J. D. Frailty and protein-energy wasting in elderly patients with end stage kidney disease. J. Am. Soc. Nephrol. 24, 337–351 (2013).
Neto, A. W. G. et al. Protein intake, fatigue and quality of life in stable outpatient kidney transplant recipients. Nutrients https://doi.org/10.3390/nu12082451 (2020).
Kalantar-Zadeh, K. et al. Dietary restrictions in dialysis patients: is there anything left to eat? Semin. Dial. 28, 159–168 (2015).
Finkelstein, F. O., West, W., Gobin, J., Finkelstein, S. H. & Wuerth, D. Spirituality, quality of life and the dialysis patient. Nephrol. Dial. Transplant. 22, 2432–2434 (2007).
Petrie, K. J. & Weinman, J. More focus needed on symptom appraisal. J. Psychosom. Res. 54, 401–403 (2003).
Stanford, J. et al. Associations among plant-based diet quality, uremic toxins, and gut microbiota profile in adults undergoing hemodialysis therapy. J. Ren. Nutr. 31, 177–188 (2021).
Pignanelli, M. et al. Moderate renal impairment and toxic metabolites produced by the intestinal microbiome: dietary implications. J. Ren. Nutr. 29, 55–64 (2019).
Davis, I. & Liu, A. What is the tryptophan kynurenine pathway and why is it important to neurotherapeutics? Expert Rev. Neurother. 15, 719–721 (2015).
Kim, H. et al. Brain indoleamine 2,3-dioxygenase contributes to the comorbidity of pain and depression. J. Clin. Invest. 122, 2940–2954 (2012).
Ravid, J. D., Kamel, M. H. & Chitalia, V. C. Uraemic solutes as therapeutic targets in CKD-associated cardiovascular disease. Nat. Rev. Nephrol. 17, 402–416 (2021).
Chiarugi, A., Calvani, M., Meli, E., Traggiai, E. & Moroni, F. Synthesis and release of neurotoxic kynurenine metabolites by human monocyte-derived macrophages. J. Neuroimmunol. 120, 190–198 (2001).
Li, S. et al. The role of bacteria and its derived metabolites in chronic pain and depression: recent findings and research progress. Int. J. Neuropsychopharmacol. 23, 26–41 (2019).
Fujigaki, H., Yamamoto, Y. & Saito, K. l-Tryptophan–kynurenine pathway enzymes are therapeutic target for neuropsychiatric diseases: focus on cell type differences. Neuropharmacology 112, 264–274 (2017).
Cryan, J. F. & Dinan, T. G. Mind-altering microorganisms: the impact of the gut microbiota on brain and behaviour. Nat. Rev. Neurosci. 13, 701–712 (2012).
Martin, C. R., Osadchiy, V., Kalani, A. & Mayer, E. A. The brain–gut–microbiome axis. Cell Mol. Gastroenterol. Hepatol. 6, 133–148 (2018).
O’Mahony, L. et al. Lactobacillus and Bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology 128, 541–551 (2005).
Caspani, G., Kennedy, S., Foster, J. A. & Swann, J. Gut microbial metabolites in depression: understanding the biochemical mechanisms. Microb. Cell 6, 454–481 (2019).
Lau, W. L., Kalantar-Zadeh, K. & Vaziri, N. D. The gut as a source of inflammation in chronic kidney disease. Nephron 130, 92–98 (2015).
Gelfand, S. L., Scherer, J. S. & Koncicki, H. M. Kidney supportive care: core curriculum 2020. Am. J. Kidney Dis. 75, 793–806 (2020).
Zarantonello, D., Rhee, C. M., Kalantar-Zadeh, K. & Brunori, G. Novel conservative management of chronic kidney disease via dialysis-free interventions. Curr. Opin. Nephrol. Hypertens. 30, 97–107 (2021).
You, A. et al. Symptom clusters in a diverse prospective hemodialysis cohort. J. Am. Soc. Neph. https://www.asn-online.org/education/kidneyweek/2021/program-abstract.aspx?controlId=3612446 (2021).
Tong, A. et al. Implementing core outcomes in kidney disease: report of the Standardized Outcomes in Nephrology (SONG) implementation workshop. Kidney Int. 94, 1053–1068 (2018).
The value of engagement. PCORI https://www.pcori.org/about-us/our-programs/engagement/public-and-patient-engagement/value-engagement (2018).
Bonventre, J. V. et al. A technology roadmap for innovative approaches to kidney replacement therapies: a catalyst for change. Clin. J. Am. Soc. Nephrol. 14, 1539–1547 (2019).
Vilar, E. et al. A multicenter feasibility randomized controlled trial to assess the impact of incremental versus conventional initiation of hemodialysis on residual kidney function. Kidney Int. https://doi.org/10.1016/j.kint.2021.07.025 (2021).
Kalantar-Zadeh, K., Jafar, T. H., Nitsch, D., Neuen, B. L. & Perkovic, V. Chronic kidney disease. Lancet 398, 786–802 (2021).
Gedney, N. & Kalantar-Zadeh, K. Dialysis patient-centeredness and precision medicine: focus on incremental home hemodialysis and preserving residual kidney function. Semin. Nephrol. 38, 426–432 (2018).
Mathew, A. T., Obi, Y., Rhee, C. M., Chou, J. A. & Kalantar-Zadeh, K. Incremental dialysis for preserving residual kidney function — does one size fit all when initiating dialysis? Semin. Dial. 31, 343–352 (2018).
Kong, J. H., Davies, M. R. & Mount, P. F. The relationship between residual kidney function and symptom burden in hemodialysis patients. Intern. Med. J. https://doi.org/10.1111/imj.14775 (2020).
Mehrotra, R. Advancing American kidney health: an introduction. Clin. J. Am. Soc. Nephrol. 14, 1788 (2019).
Wong, J., Vilar, E., Davenport, A. & Farrington, K. Incremental haemodialysis. Nephrol. Dial. Transpl. 30, 1639–1648 (2015).
Murea, M. et al. Renal replacement treatment initiation with twice-weekly versus thrice-weekly haemodialysis in patients with incident dialysis-dependent kidney disease: rationale and design of the TWOPLUS pilot clinical trial. BMJ Open 11, e047596 (2021).
Murea, M. & Kalantar-Zadeh, K. Incremental and twice-weekly hemodialysis program in practice. Clin. J. Am. Soc. Nephrol. 16, 147–149 (2020).
Da Silva-Gane, M. et al. Quality of life and survival in patients with advanced kidney failure managed conservatively or by dialysis. Clin. J. Am. Soc. Nephrol. 7, 2002–2009 (2012).
Rhee, C. M., Nguyen, D. V., Nyamathi, A. & Kalantar-Zadeh, K. Conservative vs. preservative management of chronic kidney disease: similarities and distinctions. Curr. Opin. Nephrol. Hypertens. 29, 92–102 (2020).
Kalantar-Zadeh, K. & Li, P. K. Strategies to prevent kidney disease and its progression. Nat. Rev. Nephrol. 16, 129–130 (2020).
Parikh, R. B., Kirch, R. A., Smith, T. J. & Temel, J. S. Early specialty palliative care — translating data in oncology into practice. N. Engl. J. Med. 369, 2347–2351 (2013).
Kalantar-Zadeh, K. & Fouque, D. Nutritional management of chronic kidney disease. N. Engl. J. Med. 377, 1765–1776 (2017).
Kalantar-Zadeh, K. et al. Plant-dominant low-protein diet for conservative management of chronic kidney disease. Nutrients 12, 1931 (2020).
Yu, J. Z. et al. There’s no place like home: 35-year patient survival on home hemodialysis. Semin. Dial. 31, 300–304 (2018).
Joshi, S., McMacken, M. & Kalantar-Zadeh, K. Plant-based diets for kidney disease: a guide for clinicians. Am. J. Kidney Dis. 77, 287–296 (2021).
Koppe, L. et al. Editorial: a call for a better understanding of the role of dietary amino acids and posttranslational protein modifications of microbiome in the progression of CKD. Nephrol. Dial. Transpl. https://doi.org/10.1093/ndt/gfab033 (2021).
Maki, K. A. et al. Considerations when designing a microbiome study: implications for nursing science. Biol. Res. Nurs. 21, 125–141 (2019).
Sumida, K., Lau, W. L., Kovesdy, C. P., Kalantar-Zadeh, K. & Kalantar-Zadeh, K. Microbiome modulation as a novel therapeutic approach in chronic kidney disease. Curr. Opin. Nephrol. Hypertens. 30, 75–84 (2021).
Coyle, P. K. Symptom management and lifestyle modifications in multiple sclerosis. Continuum 22, 815–836 (2016).